HS-210
Current Status: Pre-clinical development

Heat Biologics is currently developing an ImPACT-based drug for the treatment of patients with advanced stage pancreatic cancer. 

About Pancreatic Cancer

The National Cancer Institute estimates that in 2009 over 40,000 people in the United States will be diagnosed with pancreatic cancer. Unfortunately, the vast majority of these patients will die of their disease within the first two years of diagnosis because effective treatments are not available. Despite decades of intensive research into new treatments for pancreatic cancer, little progress has been made. To date, most approaches that have been attempted to treat pancreatic cancer have focused on new surgical techniques, radiation therapy and chemotherapy. It is because of the failure of these approaches that new treatments with biological modifier therapies such as HeatShock must be tried.

Click here for more information on pancreatic cancer.